5 Questions About the FDA's Fast-Track Push for Psychedelic Treatments
The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.
5 Questions About the FDA’s Fast-Track Push for Psychedelic Treatments The Food and Drug Administration has awarded priority review vouchers to three companies. These companies are developing psychedelic-based treatments for mental health conditions. Two companies are studying psilocybin for treatment-resistant depression, and one is studying methylone for PTSD.
- FDA awarded priority review vouchers to three companies.
- Companies are developing psychedelic-based treatments for mental health.
- Two companies are studying psilocybin for hard-to-treat depression.
- One company is studying methylone for PTSD.
Write a comment